Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is listed today as Stoke Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2018 | $90 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Stoke Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).
SEC Form D · Nov 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2018
That is all the official record says: Stoke Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Stoke Therapeutics, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Apple Tree Partners IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-2CONVERTIBLE and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ATP III GP, Ltd. | Company | not stated | not stated | Held Series A, A-2CONVERTIBLE and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| RTW Investments, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Seth Loring Harrison | Person | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 14 investors.
Largest shareholders today
Institutions holding Stoke Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$165 M9.71%
- RTW Investments, LP$146 M8.60%
- FMR LLC$130 M7.65%
- Wellington Management Group LLP$122 M7.16%
- Lynx1 Capital Management LP$101 M5.96%
- Redmile Group, LLC$101 M5.92%
- BVF Inc/il$94 M5.52%
- Morgan Stanley$83 M4.91%
- Vanguard Capital Management LLC$71 M4.18%
- State Street Corp$68 M4.00%
- Price T Rowe Associates Inc /MD/$63 M3.71%
- T. Rowe Price Investment Management, Inc.$54 M3.16%
- Siren, L.L.C.$52 M3.05%
- Janus Henderson Group Ltd.$51 M3.02%
- Deerfield Management Company, L.P.$47 M2.79%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adrian R. Krainer | Executive officer | Nov 2018 |
| Barry M. Ticho | Executive officer | Nov 2018 |
| Charles R. Allerson | Executive officer | Nov 2018 |
| Edward M. Kaye | Executive officer | Nov 2018 |
| Gene M. Liau | Executive officer | Nov 2018 |
| Huw M. Nash | Executive officer | Nov 2018 |
| Isabel M. Aznarez | Executive officer | Nov 2018 |
| Meena R. Meena | Executive officer | Nov 2018 |
| Adrian R. Krainer | Director | Nov 2018 |
| Arthur A. Levin | Director | Nov 2018 |
| Arthur W. Tzianabos | Director | Nov 2018 |
| Edward M. Kaye | Director | Nov 2018 |
| Samuel W. Hall | Director | Nov 2018 |
| Seth L. Harrison | Director | Nov 2018 |
| Adrian R. Krainer | Promoter | Nov 2018 |
| Isabel M. Aznarez | Promoter | Nov 2018 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.